Business
Biofrontera is a U.S.-based dermatology company focused on photodynamic therapy products including Ameluz and RhodoLED lamp systems for actinic keratosis.
Biofrontera grew revenue and narrowed its loss, but cash burn worsened and Altman-Z stayed in distress.
The read at a glance✓ Audited against SEC data
- Business mix — Dermatology PDT productsNote
- Revenue — $41.7M, up 11.7%OK
- Losses — Net loss narrowed to $10.5MOK
- Cash — Free cash flow fell to -$13.4MWatch
- Equity — Equity rose to $10.5MOK
- Insiders — 0 purchases / 0 salesNote
- Accounting — Altman-Z distress; other fields unavailableWatch
Where the revenue comes from
Fiscal 2024, as Biofrontera Inc. reports it. History and quarterly detail are in the app.
- Second A And R Ameluz LSA$150.0M
- Xepi License And Supply Agreement$25.0M
Leadership changes
From Biofrontera Inc.'s own filings, the day they're filed.
- Heikki Lanckriet · Director · appointmenteff. 2023-07-07
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-14
- 10-Q · Quarterly report2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Biofrontera Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.